Abdala is a subunit vaccine, developed for vaccination against the SARS-CoV-2 virus. As active pharmaceutical ingredient it contains the receptor-binding domain (RBD) and as inactive ingredients it contains phosphate salts and aluminum hydroxide gel adjuvant. It is manufactured in the Center for Genetic Engineering and Biotechnology (Havana, Cuba), with a production system of more than twenty years of experience, complying with current good production practices and in accordance with the recommendations of the World Health Organization ( WHO).
